Livzon Pharmaceutical Group Inc. (1513.HK)
1513.HK Stock Price Chart
Explore Livzon Pharmaceutical Group Inc. interactive price chart. Choose custom timeframes to analyze 1513.HK price movements and trends.
1513.HK Company Profile
Discover essential business fundamentals and corporate details for Livzon Pharmaceutical Group Inc. (1513.HK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
16 Jan 2014
Employees
9.07K
Website
https://www.livzon.com.cnCEO
Yanggang Tang
Description
Livzon Pharmaceutical Group Inc. engages in the research, development, production, and sale of pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People's Republic of China. The company offers Ilaprazole enteric coated tablets for the treatment of duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection; Urofollitropin for injection to treat anovulation and sufferers; Perospirone Hydrochloride for the treatment of schizophrenia; Anti-viral Granules to treat upper respiratory tract infection and influenza; and Shenqi Fuzheng Injection for the treatment of weakness and tiredness, lassitude, spontaneous sweating, and vertigo, as well as for the patients of lung and stomach cancer. It also offers diagnostic reagents, such as diagnostic kit for IgM/IgG antibody to coronavirus; nucleic acid test kit for human immunodeficiency virus type 1; antinuclear antibody test kits; interferon-gamma release assays test kits; and rapid test for mycoplasma pneumoniae IgM antibody. In addition, the company provides biochemical drugs, microbiological preparations, biologic products, Chinese drug preparations and pharmaceutical raw materials, and antibiotics. It also exports its products. The company was founded in 1985 and is headquartered in Zhuhai, China.
1513.HK Financial Timeline
Browse a chronological timeline of Livzon Pharmaceutical Group Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 21 Apr 2026
Upcoming earnings on 24 Mar 2026
Upcoming earnings on 21 Oct 2025
Earnings released on 20 Aug 2025
EPS came in at $0.76 surpassing the estimated $0.63 by +20.96%, while revenue for the quarter reached $3.39B , beating expectations by +20.06%.
Dividend declared on 13 Jun 2025
A dividend of $1.20 per share was announced, adjusted to $1.20. The dividend was paid on 11 Jul 2025.
Earnings released on 21 Apr 2025
EPS came in at $0.76 surpassing the estimated $0.74 by +1.48%, while revenue for the quarter reached $3.39B , beating expectations by +8.27%.
Earnings released on 26 Mar 2025
EPS came in at $0.46 surpassing the estimated $0.43 by +7.09%, while revenue for the quarter reached $2.90B , beating expectations by +4.70%.
Earnings released on 23 Oct 2024
EPS came in at $0.54 falling short of the estimated $0.57 by -5.26%, while revenue for the quarter reached $3.10B , beating expectations by +11.65%.
Earnings released on 22 Aug 2024
EPS came in at $0.62 surpassing the estimated $0.55 by +12.73%, while revenue for the quarter reached $3.26B , missing expectations by -5.16%.
Dividend declared on 8 Jul 2024
A dividend of $1.48 per share was announced, adjusted to $1.48. The dividend was paid on 5 Aug 2024.
Earnings released on 23 Apr 2024
EPS came in at $0.65 surpassing the estimated $0.61 by +6.56%, while revenue for the quarter reached $3.51B , missing expectations by -8.03%.
Earnings released on 28 Mar 2024
EPS came in at $0.38 falling short of the estimated $0.43 by -11.63%, while revenue for the quarter reached $3.07B , missing expectations by -6.62%.
Earnings released on 24 Oct 2023
EPS came in at $0.50 falling short of the estimated $0.61 by -18.03%, while revenue for the quarter reached $3.18B , missing expectations by -14.96%.
Earnings released on 23 Aug 2023
EPS came in at $0.60 falling short of the estimated $0.63 by -4.76%, while revenue for the quarter reached $3.54B , missing expectations by -7.22%.
Dividend declared on 4 Jul 2023
A dividend of $1.74 per share was announced, adjusted to $1.74. The dividend was paid on 31 Jul 2023.
Earnings released on 20 Apr 2023
EPS came in at $0.49 falling short of the estimated $0.65 by -24.63%, while revenue for the quarter reached $3.58B , missing expectations by -16.99%.
Earnings released on 31 Mar 2023
EPS came in at $0.43 surpassing the estimated $0.40 by +7.50%, while revenue for the quarter reached $3.90B , beating expectations by +13.05%.
Earnings released on 25 Oct 2022
EPS came in at $0.52 surpassing the estimated $0.51 by +1.96%, while revenue for the quarter reached $3.50B , missing expectations by -7.12%.
Earnings released on 9 Aug 2022
EPS came in at $0.50 falling short of the estimated $0.60 by -16.67%, while revenue for the quarter reached $3.31B , missing expectations by -14.61%.
Dividend declared on 30 May 2022
A dividend of $1.51 per share was announced, adjusted to $1.51. The dividend was paid on 24 Jun 2022.
Earnings released on 21 Apr 2022
EPS came in at $0.59 falling short of the estimated $0.66 by -10.61%, while revenue for the quarter reached $4.29B , beating expectations by +4.17%.
Earnings released on 29 Mar 2022
EPS came in at $0.35 falling short of the estimated $0.38 by -7.89%, while revenue for the quarter reached $3.30B , missing expectations by -3.46%.
Earnings released on 25 Oct 2021
EPS came in at $0.41 falling short of the estimated $0.67 by -38.81%, while revenue for the quarter reached $3.78B .
Earnings released on 24 Aug 2021
EPS came in at $0.59 matching the estimated $0.59, while revenue for the quarter reached $3.46B .
Dividend declared on 1 Jun 2021
A dividend of $1.51 per share was announced, adjusted to $1.51. The dividend was paid on 25 Jun 2021.
Earnings released on 21 Apr 2021
EPS came in at $0.55 falling short of the estimated $0.65 by -15.38%, while revenue for the quarter reached $3.97B .
Earnings released on 23 Mar 2021
EPS came in at $0.50 surpassing the estimated $0.31 by +61.29%, while revenue for the quarter reached $3.08B .
Earnings released on 23 Oct 2020
EPS came in at $0.44 surpassing the estimated $0.41 by +7.32%, while revenue for the quarter reached $3.23B .
1513.HK Stock Performance
Access detailed 1513.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.